Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1999 June;41(2) > Panminerva Medica 1999 June;41(2):93-7





A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6




Panminerva Medica 1999 June;41(2):93-7

language: English

The ­absence of cor­re­la­tion ­between immu­nor­e­gu­la­to­ry T ­cells and ­induced lym­phop­ro­lif­er­a­tive ­response in treat­ed B-chron­ic lym­pho­cyt­ic leu­ke­mia ­patients

Milosevic D., Marin­ko­vic M., Colo­vic M.*, Jelic S.

From the Institute for Oncology and Radiology of Serbia, Belgrade, Yugoslavia
* Institute of Haematology, University Clinical Center, Belgrade, Yugoslavia


Background. Many ­data sug­gest T ­cell func­tion­al impair­ment in B-­cell chron­ic lym­pho­cyt­ic leu­ke­mia (B-CLL). The mech­a­nism respon­sible for ­this phe­nom­e­non is ­still unre­solved.
Methods. In 88 B-CLL ­patients (RAI II-IV) the rela­tion­ship ­between immu­nor­e­gu­la­to­ry T ­cells and PHA ­induced lym­phop­ro­lif­er­a­tive ­response (LPR) was ana­lysed ­before and ­after the ther­a­py. The num­ber of periph­er­al ­blood CD3+, CD4+ and CD8+ T lym­pho­cytes was deter­mined by indi­rect immu­no­flu­o­res­cence ­assay ­using mono­clo­nal anti­bod­ies. LPR was esti­mat­ed in ­whole ­blood cul­ture meth­od.
Results. The abso­lute num­ber of CD3+,CD4+ and CD8+ ­cells in untreat­ed CLL ­patients was ­much high­er ­than in ­healthy con­trols (n=26), but the per­cent­ag­es of ­these sub­pop­u­la­tions, CD4/CD8 ­ratio and LPR to PHA ­were sig­nif­i­cant­ly (p<0.00001) ­decreased. The chem­o­ther­a­py ­induced a sig­nif­i­cant ­rise of CD3+ and CD4+ per­cent­ag­es (p<0.006Conclusions. These ­data indi­cate ­some pro­found lym­phoid ­cell ­defect in CLL ­patients affect­ing CD8+ pro­life­ra­tion as ­well as LPR.

top of page

Publication History

Cite this article as

Corresponding author e-mail